{
    "organizations": [],
    "uuid": "1a24849accbfc5fb8da4b0488d172105b3d76d7a",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/05/01/globe-newswire-ultragenyx-to-host-conference-call-for-first-quarter-2018-financial-results-and-corporate-update.html",
    "ord_in_thread": 0,
    "title": "Ultragenyx to Host Conference Call for First Quarter 2018 Financial Results and Corporate Update",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "NOVATO, Calif., May 01, 2018 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it will host a conference call on Monday, May 7, 2018 at 5pm ET to discuss first quarter 2018 financial results and provide a corporate update.\nThe live and replayed webcast of the call will be available through the company’s website at http://ir.ultragenyx.com/events.cfm . To participate in the live call by phone, dial 855-797-6910 (USA) or 262-912-6260 (international) and enter the passcode 3748439. The replay of the call will be available for one year.\nAbout Ultragenyx\nUltragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies.\nThe company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.\nFor more information on Ultragenyx, please visit the company’s website at www.ultragenyx.com .\nContact Ultragenyx Pharmaceutical Inc.\nInvestors & Media\nDanielle Keatley\n415-475-6876\nSource:Ultragenyx Pharmaceutical Inc.",
    "published": "2018-05-01T16:30:00.000+03:00",
    "crawled": "2018-05-01T17:13:15.007+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "novato",
        "may",
        "globe",
        "newswire",
        "ultragenyx",
        "pharmaceutical",
        "nasdaq",
        "rare",
        "biopharmaceutical",
        "company",
        "focused",
        "development",
        "novel",
        "product",
        "rare",
        "disease",
        "today",
        "announced",
        "host",
        "conference",
        "call",
        "monday",
        "may",
        "5pm",
        "et",
        "discus",
        "first",
        "quarter",
        "financial",
        "result",
        "provide",
        "corporate",
        "update",
        "live",
        "replayed",
        "webcast",
        "call",
        "available",
        "company",
        "website",
        "http",
        "participate",
        "live",
        "call",
        "phone",
        "dial",
        "usa",
        "international",
        "enter",
        "passcode",
        "replay",
        "call",
        "available",
        "one",
        "year",
        "ultragenyx",
        "ultragenyx",
        "biopharmaceutical",
        "company",
        "committed",
        "bringing",
        "patient",
        "novel",
        "product",
        "treatment",
        "rare",
        "disease",
        "focus",
        "serious",
        "debilitating",
        "genetic",
        "disease",
        "founded",
        "company",
        "rapidly",
        "built",
        "diverse",
        "portfolio",
        "product",
        "candidate",
        "potential",
        "address",
        "disease",
        "unmet",
        "medical",
        "need",
        "high",
        "biology",
        "treatment",
        "clear",
        "approved",
        "therapy",
        "company",
        "led",
        "management",
        "team",
        "experienced",
        "development",
        "commercialization",
        "rare",
        "disease",
        "therapeutic",
        "ultragenyx",
        "strategy",
        "predicated",
        "upon",
        "time",
        "drug",
        "development",
        "goal",
        "delivering",
        "safe",
        "effective",
        "therapy",
        "patient",
        "utmost",
        "urgency",
        "information",
        "ultragenyx",
        "please",
        "visit",
        "company",
        "website",
        "contact",
        "ultragenyx",
        "pharmaceutical",
        "investor",
        "medium",
        "danielle",
        "keatley",
        "source",
        "ultragenyx",
        "pharmaceutical",
        "inc"
    ]
}